FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142232389> ?p ?o ?g. }

• W2142232389 endingPage "1195" @default.
• W2142232389 startingPage "1180" @default.
• W2142232389 abstract "The efficacy of topiramate (TPM) as an adjunctive treatment for epilepsy has been established in placebo-controlled clinical trials. Clinical trials of antiepileptic monotherapy usually evaluate low and high doses of study drug or compare study drug with another active agent.This article reviews available evidence for the use of TPM as monotherapy in patients with newly or recently diagnosed epilepsy.A search of MEDLINE, EMBASE, BIOSIS, SCISEARCH, and the Cochrane Database of Systematic Reviews (all years) for reports of controlled trials of TPM monotherapy in patients with recently diagnosed (within the previous 3 years) epilepsy was conducted in January 2008 using the terms topiramate, epilepsy, newly diagnosed, recently diagnosed, and monotherapy. Identified trials were included in the review if they were published in peer-reviewed journals and enrolled > or = 20 patients.Three randomized, double-blind, controlled trials met the criteria for inclusion in the review. In a comparison of TPM 50 and 500 mg/d, the higher dose was associated with significantly greater freedom from seizures at 6 months compared with the lower dose (54% vs 39%, respectively; P = 0.02). The time to first seizure was significantly associated with mean plasma TPM concentrations (P = 0.015). In a comparison of TPM 50 and 400 mg/d, the time to first seizure was significantly longer with the higher dose compared with the lower dose (P<0.001, Kaplan-Meier analysis), and the probability of 12-month seizure freedom was significantly higher (76% vs 59%, respectively; P = 0.001). Again, the time to first seizure was significantly associated with mean plasma TPM concentrations (P = 0.029). In a comparative study of TPM 100 and 200 mg/d, carbamazepine 600 mg/d, and valproate 1250 mg/d, there was no significant difference in rates of 6-month seizure freedom with TPM 100 and 200 mg/d (49% and 44%, respectively), carbamazepine (44%), and valproate (44%). Adverse events in the 3 studies were similar between TPM dose groups, although the incidence generally increased with increasing doses, occurred early in treatment, and decreased with prolonged therapy. In a pooled analysis of the 3 trials, the most commonly occurring adverse events during dose titration were paresthesia (25%), fatigue (16%), dizziness (13%), somnolence (13%), and nausea (10%); the most frequent adverse events during maintenance therapy were headache (20%), decreased appetite (11%), and weight loss (11%).In the 3 studies reviewed, TPM monotherapy was effective and generally well tolerated in patients with newly diagnosed epilepsy." @default.
• W2142232389 created "2016-06-24" @default.
• W2142232389 creator A5023280553 @default.
• W2142232389 creator A5035657409 @default.
• W2142232389 creator A5052367335 @default.
• W2142232389 creator A5061862920 @default.
• W2142232389 creator A5091766224 @default.
• W2142232389 date "2008-07-01" @default.
• W2142232389 modified "2023-09-26" @default.
• W2142232389 title "Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy" @default.
• W2142232389 cites W1491157696 @default.
• W2142232389 cites W1546292582 @default.
• W2142232389 cites W1553852865 @default.
• W2142232389 cites W1966057128 @default.
• W2142232389 cites W1973491611 @default.
• W2142232389 cites W1974311184 @default.
• W2142232389 cites W1979566021 @default.
• W2142232389 cites W1979865603 @default.
• W2142232389 cites W1985043270 @default.
• W2142232389 cites W1989582194 @default.
• W2142232389 cites W1993706660 @default.
• W2142232389 cites W1994430795 @default.
• W2142232389 cites W1998338808 @default.
• W2142232389 cites W1998394528 @default.
• W2142232389 cites W1998615413 @default.
• W2142232389 cites W2003904508 @default.
• W2142232389 cites W2004951945 @default.
• W2142232389 cites W2008464332 @default.
• W2142232389 cites W2011911182 @default.
• W2142232389 cites W2012891482 @default.
• W2142232389 cites W2020473988 @default.
• W2142232389 cites W2032109763 @default.
• W2142232389 cites W2033585926 @default.
• W2142232389 cites W2034278159 @default.
• W2142232389 cites W2037292769 @default.
• W2142232389 cites W2037338708 @default.
• W2142232389 cites W2038908933 @default.
• W2142232389 cites W2039100965 @default.
• W2142232389 cites W2043242122 @default.
• W2142232389 cites W2043285983 @default.
• W2142232389 cites W2049772989 @default.
• W2142232389 cites W2056735380 @default.
• W2142232389 cites W2071674869 @default.
• W2142232389 cites W2080494081 @default.
• W2142232389 cites W2082270842 @default.
• W2142232389 cites W2083322751 @default.
• W2142232389 cites W2086001349 @default.
• W2142232389 cites W2093392404 @default.
• W2142232389 cites W2105641288 @default.
• W2142232389 cites W2105966214 @default.
• W2142232389 cites W2106096775 @default.
• W2142232389 cites W2117449343 @default.
• W2142232389 cites W2117606859 @default.
• W2142232389 cites W2124847836 @default.
• W2142232389 cites W2125196788 @default.
• W2142232389 cites W2125397400 @default.
• W2142232389 cites W2126685531 @default.
• W2142232389 cites W2129745199 @default.
• W2142232389 cites W2130981472 @default.
• W2142232389 cites W2135408849 @default.
• W2142232389 cites W2138521331 @default.
• W2142232389 cites W2141637053 @default.
• W2142232389 cites W2145564411 @default.
• W2142232389 cites W2147974822 @default.
• W2142232389 cites W2153884620 @default.
• W2142232389 cites W2165630646 @default.
• W2142232389 cites W2168508835 @default.
• W2142232389 cites W2168724473 @default.
• W2142232389 cites W2168915562 @default.
• W2142232389 cites W2171332093 @default.
• W2142232389 cites W4245946884 @default.
• W2142232389 cites W4253837878 @default.
• W2142232389 cites W4295332804 @default.
• W2142232389 doi "https://doi.org/10.1016/s0149-2918(08)80045-8" @default.
• W2142232389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18691980" @default.
• W2142232389 hasPublicationYear "2008" @default.
• W2142232389 type Work @default.
• W2142232389 sameAs 2142232389 @default.
• W2142232389 citedByCount "36" @default.
• W2142232389 countsByYear W21422323892012 @default.
• W2142232389 countsByYear W21422323892013 @default.
• W2142232389 countsByYear W21422323892014 @default.
• W2142232389 countsByYear W21422323892015 @default.
• W2142232389 countsByYear W21422323892016 @default.
• W2142232389 countsByYear W21422323892017 @default.
• W2142232389 countsByYear W21422323892018 @default.
• W2142232389 countsByYear W21422323892019 @default.
• W2142232389 countsByYear W21422323892020 @default.
• W2142232389 countsByYear W21422323892021 @default.
• W2142232389 countsByYear W21422323892022 @default.
• W2142232389 crossrefType "journal-article" @default.
• W2142232389 hasAuthorship W2142232389A5023280553 @default.
• W2142232389 hasAuthorship W2142232389A5035657409 @default.
• W2142232389 hasAuthorship W2142232389A5052367335 @default.
• W2142232389 hasAuthorship W2142232389A5061862920 @default.
• W2142232389 hasAuthorship W2142232389A5091766224 @default.
• W2142232389 hasConcept C118552586 @default.
• W2142232389 hasConcept C126322002 @default.

• next